



# indoco remedies limited

R & D CENTRE :- R-92 - 93. T.T.C. INDL. AREA, MIDC, THANE BELAPUR ROAD, RABALE, NAVI MUMBAI - 400 701.  
PHONES : [91-22] 2769 3300 / 2769 8899 • FAX : [91-22] 2769 5500 • www.indoco.com

October 7, 2019

To  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza', C- 1, Block G,  
Bandra-Kurla Complex,  
Bandra (E)  
Mumbai 400051  
Scrip Code: INDOCO

To  
Corporate Relationship Department  
BSE Limited  
1<sup>st</sup> Floor, New Trading Ring  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400001  
Scrip Code: 532612

Dear Sirs

**Sub: Disclosure under Regulation 30 of LODR Regulations 2015  
Indoco receives ANDA approval for Rasagiline tablets from USFDA**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,  
please find Press Release for your information and record.

**For Indoco Remedies Limited**

  
Jayshankar Menon  
Company Secretary



## PRESS RELEASE

### Indoco receives ANDA approval for Rasagiline tablets

October 7, 2019, Mumbai

Indoco Remedies Ltd. has received the final approval for its Abbreviated New Drug Application (ANDA) for Rasagiline 0.5 mg and 1 mg tablets from the United States Food & Drug Administration (USFDA). Rasagiline is used for treatment of Parkinson's disease. The market size of this product in the US as per IMS 2018 data is US\$ 105 million.

Commenting on this encouraging development, Ms. Aditi Kare Panandikar, Managing Director – Indoco Remedies Ltd., said, “This is the first ANDA approval for Indoco after receipt of warning letter in March 2017 for Goa plant II and III. The Company has 32 ANDAs pending for approval for different dosage forms from this site.”

#### **About Indoco Remedies Limited:**

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD140 million Company, employs over 5500 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, MCC-South Africa, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from around 3,10,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Kidodent, Carmicide, Bactogard, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis)- USA and ASPEN-South Africa.

For more details on Indoco, you may visit [www.indoco.com](http://www.indoco.com)

#### **For Media Inquiries Please Contact:**

Mr. Vilas V. Nagare

Mobile: 9820215745

E-mail: [vilasn@indoco.com](mailto:vilasn@indoco.com) / [corpcom@indoco.com](mailto:corpcom@indoco.com)

